BioCentury
ARTICLE | Clinical News

AnaptysBio shares double on atopic dermatitis data

October 10, 2017 10:18 PM UTC

AnaptysBio Inc. (NASDAQ:ANAB) gained $35.41 (101%) to $70.41 on Tuesday after reporting data from a Phase IIa trial of lead program ANB020, an antibody against IL-33, to treat atopic dermatitis. An AnaptysBio spokesperson told BioCentury the study had no prespecified primary endpoint, but said the study "achieved the trial protocol objective."

The trial's key efficacy objective evaluated whether ANB020 improved Eczema Area and Severity Index score by 50% (EASI-50) in at least 50% of moderate to severe atopic dermatitis patients four weeks after dosing. Among the trial's 12 patients, 83% achieved an EASI-50 at day 29, while 75% did so at both day 15 and at day 57. The candidate led to EASI-75 responses in 25%, 33% and 42% of patients at days 15, 29 and 57, respectively. From baseline to each timepoint, the molecule reduced average EASI scores by 58%, 61% and 62%...